Skip to main content
Microbiological Reviews logoLink to Microbiological Reviews
. 1995 Sep;59(3):387–405. doi: 10.1128/mr.59.3.387-405.1995

Immune regulation in Epstein-Barr virus-associated diseases.

R Khanna 1, S R Burrows 1, D J Moss 1
PMCID: PMC239366  PMID: 7565411

Abstract

Epstein-Barr virus (EBV) is a member of the human herpesvirus family and, like many other herpesviruses, maintains a lifelong latent association with B lymphocytes and a permissive association with stratified epithelium in the oropharynx. Clinical manifestations of primary EBV infection range from acute infectious mononucleosis to an asymptomatic persistent infection. EBV is also associated with a number of malignancies in humans. This review discusses features of the biology of the virus, both in cell culture systems and in the natural host, before turning to the role of the immune system in controlling EBV infection in healthy individuals and in individuals with EBV-associated diseases. Cytotoxic T cells that recognize virally determined epitopes on infected cells make up the major effector arm and control the persistent infection. In contrast, the options for immune control of EBV-associated malignancies are more restricted. Not only is antigen expression restricted to a single nuclear antigen, EBNA1, but also these tumor cells are unable to process EBV latent antigens, presumably because of a transcriptional defect in antigen-processing genes (such as TAP1 and TAP2). The likelihood of producing a vaccine capable of controlling the acute viral infection and EBV-associated malignancies is also discussed.

Full Text

The Full Text of this article is available as a PDF (402.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbot S. D., Rowe M., Cadwallader K., Ricksten A., Gordon J., Wang F., Rymo L., Rickinson A. B. Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J Virol. 1990 May;64(5):2126–2134. doi: 10.1128/jvi.64.5.2126-2134.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Adldinger H. K., Delius H., Freese U. K., Clarke J., Bornkamm G. W. A putative transforming gene of Jijoye virus differs from that of Epstein-Barr virus prototypes. Virology. 1985 Mar;141(2):221–234. doi: 10.1016/0042-6822(85)90253-3. [DOI] [PubMed] [Google Scholar]
  3. Alfieri C., Birkenbach M., Kieff E. Early events in Epstein-Barr virus infection of human B lymphocytes. Virology. 1991 Apr;181(2):595–608. doi: 10.1016/0042-6822(91)90893-g. [DOI] [PubMed] [Google Scholar]
  4. Allday M. J., Crawford D. H., Griffin B. E. Epstein-Barr virus latent gene expression during the initiation of B cell immortalization. J Gen Virol. 1989 Jul;70(Pt 7):1755–1764. doi: 10.1099/0022-1317-70-7-1755. [DOI] [PubMed] [Google Scholar]
  5. Allday M. J., Kundu D., Finerty S., Griffin B. E. CpG methylation of viral DNA in EBV-associated tumours. Int J Cancer. 1990 Jun 15;45(6):1125–1130. doi: 10.1002/ijc.2910450623. [DOI] [PubMed] [Google Scholar]
  6. Aman P., Lewin N., Nordström M., Klein G. EBV-activation of human B-lymphocytes. Curr Top Microbiol Immunol. 1986;132:266–271. doi: 10.1007/978-3-642-71562-4_40. [DOI] [PubMed] [Google Scholar]
  7. Anagnostopoulos I., Herbst H., Niedobitek G., Stein H. Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization. Blood. 1989 Aug 1;74(2):810–816. [PubMed] [Google Scholar]
  8. Apolloni A., Moss D., Stumm R., Burrows S., Suhrbier A., Misko I., Schmidt C., Sculley T. Sequence variation of cytotoxic T cell epitopes in different isolates of Epstein-Barr virus. Eur J Immunol. 1992 Jan;22(1):183–189. doi: 10.1002/eji.1830220127. [DOI] [PubMed] [Google Scholar]
  9. Armstrong R. W., Armstrong M. J., Yu M. C., Henderson B. E. Salted fish and inhalants as risk factors for nasopharyngeal carcinoma in Malaysian Chinese. Cancer Res. 1983 Jun;43(6):2967–2970. [PubMed] [Google Scholar]
  10. Baer R., Bankier A. T., Biggin M. D., Deininger P. L., Farrell P. J., Gibson T. J., Hatfull G., Hudson G. S., Satchwell S. C., Séguin C. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature. 1984 Jul 19;310(5974):207–211. doi: 10.1038/310207a0. [DOI] [PubMed] [Google Scholar]
  11. Bastin J., Rothbard J., Davey J., Jones I., Townsend A. Use of synthetic peptides of influenza nucleoprotein to define epitopes recognized by class I-restricted cytotoxic T lymphocytes. J Exp Med. 1987 Jun 1;165(6):1508–1523. doi: 10.1084/jem.165.6.1508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Bejarano M. T., Masucci M. G., Klein G., Klein E. T-cell-mediated inhibition of EBV-induced B-cell transformation: recognition of virus particles. Int J Cancer. 1988 Sep 15;42(3):359–364. doi: 10.1002/ijc.2910420309. [DOI] [PubMed] [Google Scholar]
  13. Bejarano M. T., Masucci M. G., Morgan A., Morein B., Klein G., Klein E. Epstein-Barr virus (EBV) antigens processed and presented by B cells, B blasts, and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation. J Virol. 1990 Mar;64(3):1398–1401. doi: 10.1128/jvi.64.3.1398-1401.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Bernheim A., Berger R., Lenoir G. Cytogenetic studies on African Burkitt's lymphoma cell lines: t(8;14), t(2;8) and t(8;22) translocations. Cancer Genet Cytogenet. 1981 Jun;3(4):307–315. doi: 10.1016/0165-4608(81)90039-x. [DOI] [PubMed] [Google Scholar]
  15. Biggin M., Bodescot M., Perricaudet M., Farrell P. Epstein-Barr virus gene expression in P3HR1-superinfected Raji cells. J Virol. 1987 Oct;61(10):3120–3132. doi: 10.1128/jvi.61.10.3120-3132.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Birx D. L., Redfield R. R., Tosato G. Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders. N Engl J Med. 1986 Apr 3;314(14):874–879. doi: 10.1056/NEJM198604033141403. [DOI] [PubMed] [Google Scholar]
  17. Bishop C. J., Moss D. J., Ryan J. M., Burrows S. R. T lymphocytes in infectious mononucleosis. II. Response in vitro to interleukin-2 and establishment of T cell lines. Clin Exp Immunol. 1985 Apr;60(1):70–77. [PMC free article] [PubMed] [Google Scholar]
  18. Blazar B., Patarroyo M., Klein E., Klein G. Increased sensitivity of human lymphoid lines to natural killer cells after induction of the Epstein-Barr viral cycle by superinfection or sodium butyrate. J Exp Med. 1980 Mar 1;151(3):614–627. doi: 10.1084/jem.151.3.614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Bornkamm G. W., Delius H., Zimber U., Hudewentz J., Epstein M. A. Comparison of Epstein-Barr virus strains of different origin by analysis of the viral DNAs. J Virol. 1980 Sep;35(3):603–618. doi: 10.1128/jvi.35.3.603-618.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Brooks J. M., Murray R. J., Thomas W. A., Kurilla M. G., Rickinson A. B. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide. J Exp Med. 1993 Sep 1;178(3):879–887. doi: 10.1084/jem.178.3.879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Burkitt D. Burkitt's lymphoma outside the known endemic areas of Africa and New Guinea. Int J Cancer. 1967 Nov 15;2(6):562–565. doi: 10.1002/ijc.2910020603. [DOI] [PubMed] [Google Scholar]
  22. Burrows S. R., Gardner J., Khanna R., Steward T., Moss D. J., Rodda S., Suhrbier A. Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. J Gen Virol. 1994 Sep;75(Pt 9):2489–2493. doi: 10.1099/0022-1317-75-9-2489. [DOI] [PubMed] [Google Scholar]
  23. Burrows S. R., Khanna R., Burrows J. M., Moss D. J. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease. J Exp Med. 1994 Apr 1;179(4):1155–1161. doi: 10.1084/jem.179.4.1155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Burrows S. R., Misko I. S., Sculley T. B., Schmidt C., Moss D. J. An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformants. J Virol. 1990 Aug;64(8):3974–3976. doi: 10.1128/jvi.64.8.3974-3976.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Burrows S. R., Rodda S. J., Suhrbier A., Geysen H. M., Moss D. J. The specificity of recognition of a cytotoxic T lymphocyte epitope. Eur J Immunol. 1992 Jan;22(1):191–195. doi: 10.1002/eji.1830220128. [DOI] [PubMed] [Google Scholar]
  26. Burrows S. R., Sculley T. B., Misko I. S., Schmidt C., Moss D. J. An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3). J Exp Med. 1990 Jan 1;171(1):345–349. doi: 10.1084/jem.171.1.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Burrows S. R., Suhrbier A., Khanna R., Moss D. J. Rapid visual assay of cytotoxic T-cell specificity utilizing synthetic peptide induced T-cell-T-cell killing. Immunology. 1992 May;76(1):174–175. [PMC free article] [PubMed] [Google Scholar]
  28. Busson P., Ganem G., Flores P., Mugneret F., Clausse B., Caillou B., Braham K., Wakasugi H., Lipinski M., Tursz T. Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas. Int J Cancer. 1988 Oct 15;42(4):599–606. doi: 10.1002/ijc.2910420422. [DOI] [PubMed] [Google Scholar]
  29. Busson P., Zhang Q., Guillon J. M., Gregory C. D., Young L. S., Clausse B., Lipinski M., Rickinson A. B., Tursz T. Elevated expression of ICAM1 (CD54) and minimal expression of LFA3 (CD58) in Epstein-Barr-virus-positive nasopharyngeal carcinoma cells. Int J Cancer. 1992 Apr 1;50(6):863–867. doi: 10.1002/ijc.2910500605. [DOI] [PubMed] [Google Scholar]
  30. Cameron K. R., Stamminger T., Craxton M., Bodemer W., Honess R. W., Fleckenstein B. The 160,000-Mr virion protein encoded at the right end of the herpesvirus saimiri genome is homologous to the 140,000-Mr membrane antigen encoded at the left end of the Epstein-Barr virus genome. J Virol. 1987 Jul;61(7):2063–2070. doi: 10.1128/jvi.61.7.2063-2070.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Carter R. L. Infectious mononucleosis: model for self-limiting lymphoproliferation. Lancet. 1975 Apr 12;1(7911):846–849. doi: 10.1016/s0140-6736(75)93014-7. [DOI] [PubMed] [Google Scholar]
  32. Chen X. Y., Pepper S. D., Arrand J. R. Prevalence of the A and B types of Epstein-Barr virus DNA in nasopharyngeal carcinoma biopsies from southern China. J Gen Virol. 1992 Feb;73(Pt 2):463–466. doi: 10.1099/0022-1317-73-2-463. [DOI] [PubMed] [Google Scholar]
  33. Clough W., McMahon J. Characterization of the Epstein-Barr virion-associated DNA polymerase as isolated from superinfected and drug-stimulated cells. Biochim Biophys Acta. 1981 Nov 27;656(1):76–85. doi: 10.1016/0005-2787(81)90029-0. [DOI] [PubMed] [Google Scholar]
  34. Cordier M., Calender A., Billaud M., Zimber U., Rousselet G., Pavlish O., Banchereau J., Tursz T., Bornkamm G., Lenoir G. M. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23. J Virol. 1990 Mar;64(3):1002–1013. doi: 10.1128/jvi.64.3.1002-1013.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Crawford D. H., Thomas J. A., Janossy G., Sweny P., Fernando O. N., Moorhead J. F., Thompson J. H. Epstein Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patient with renal allograft. Lancet. 1980 Jun 21;1(8182):1355–1356. doi: 10.1016/s0140-6736(80)91800-0. [DOI] [PubMed] [Google Scholar]
  36. Dalla-Favera R., Bregni M., Erikson J., Patterson D., Gallo R. C., Croce C. M. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824–7827. doi: 10.1073/pnas.79.24.7824. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Dambaugh T., Beisel C., Hummel M., King W., Fennewald S., Cheung A., Heller M., Raab-Traub N., Kieff E. Epstein-Barr virus (B95-8) DNA VII: molecular cloning and detailed mapping. Proc Natl Acad Sci U S A. 1980 May;77(5):2999–3003. doi: 10.1073/pnas.77.5.2999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Dambaugh T., Hennessy K., Chamnankit L., Kieff E. U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2. Proc Natl Acad Sci U S A. 1984 Dec;81(23):7632–7636. doi: 10.1073/pnas.81.23.7632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Dambaugh T., Raab-Traub N., Heller M., Beisel C., Hummel M., Cheung A., Fennewald S., King W., Kieff E. Variations among isolates of Epstein-Barr virus. Ann N Y Acad Sci. 1980;354:309–325. doi: 10.1111/j.1749-6632.1980.tb27974.x. [DOI] [PubMed] [Google Scholar]
  40. Davison A. J., Scott J. E. The complete DNA sequence of varicella-zoster virus. J Gen Virol. 1986 Sep;67(Pt 9):1759–1816. doi: 10.1099/0022-1317-67-9-1759. [DOI] [PubMed] [Google Scholar]
  41. Davison A. J., Taylor P. Genetic relations between varicella-zoster virus and Epstein-Barr virus. J Gen Virol. 1987 Apr;68(Pt 4):1067–1079. doi: 10.1099/0022-1317-68-4-1067. [DOI] [PubMed] [Google Scholar]
  42. Davison A. J., Wilkie N. M. Nucleotide sequences of the joint between the L and S segments of herpes simplex virus types 1 and 2. J Gen Virol. 1981 Aug;55(Pt 2):315–331. doi: 10.1099/0022-1317-55-2-315. [DOI] [PubMed] [Google Scholar]
  43. DeAngelis L. M., Wong E., Rosenblum M., Furneaux H. Epstein-Barr virus in acquired immune deficiency syndrome (AIDS) and non-AIDS primary central nervous system lymphoma. Cancer. 1992 Sep 15;70(6):1607–1611. doi: 10.1002/1097-0142(19920915)70:6<1607::aid-cncr2820700628>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  44. Dolyniuk M., Wolff E., Kieff E. Proteins of Epstein-Barr Virus. II. Electrophoretic analysis of the polypeptides of the nucleocapsid and the glucosamine- and polysaccharide-containing components of enveloped virus. J Virol. 1976 Apr;18(1):289–297. doi: 10.1128/jvi.18.1.289-297.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Drexler H. G. Recent results on the biology of Hodgkin and Reed-Sternberg cells. I. Biopsy material. Leuk Lymphoma. 1992 Nov;8(4-5):283–313. doi: 10.3109/10428199209051008. [DOI] [PubMed] [Google Scholar]
  46. EPSTEIN M. A., ACHONG B. G., BARR Y. M. VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. Lancet. 1964 Mar 28;1(7335):702–703. doi: 10.1016/s0140-6736(64)91524-7. [DOI] [PubMed] [Google Scholar]
  47. EPSTEIN M. A., BARR Y. M. CULTIVATION IN VITRO OF HUMAN LYMPHOBLASTS FROM BURKITT'S MALIGNANT LYMPHOMA. Lancet. 1964 Feb 1;1(7327):252–253. doi: 10.1016/s0140-6736(64)92354-2. [DOI] [PubMed] [Google Scholar]
  48. EPSTEIN M. A., HENLE G., ACHONG B. G., BARR Y. M. MORPHOLOGICAL AND BIOLOGICAL STUDIES ON A VIRUS IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. J Exp Med. 1965 May 1;121:761–770. doi: 10.1084/jem.121.5.761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Ellis P. A., Hart D. N., Colls B. M., Nimmo J. C., MacDonald J. E., Angus H. B. Hodgkin's cells express a novel pattern of adhesion molecules. Clin Exp Immunol. 1992 Oct;90(1):117–123. doi: 10.1111/j.1365-2249.1992.tb05842.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Epstein M. A., Achong B. G. Various forms of Epstein-Barr virus infection in man: established facts and a general concept. Lancet. 1973 Oct 13;2(7833):836–839. doi: 10.1016/s0140-6736(73)90874-x. [DOI] [PubMed] [Google Scholar]
  51. Fass L., Herberman R. B., Ziegler J. Delayed cutaneous hypersensitivity reactions to autologous extracts of Burkitt-lymphoma cells. N Engl J Med. 1970 Apr 2;282(14):776–780. doi: 10.1056/NEJM197004022821404. [DOI] [PubMed] [Google Scholar]
  52. Fox R. I., Luppi M., Kang H. I., Pisa P. Reactivation of Epstein-Barr virus in Sjögren's syndrome. Springer Semin Immunopathol. 1991;13(2):217–231. doi: 10.1007/BF00201470. [DOI] [PubMed] [Google Scholar]
  53. Fåhraeus R., Fu H. L., Ernberg I., Finke J., Rowe M., Klein G., Falk K., Nilsson E., Yadav M., Busson P. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer. 1988 Sep 15;42(3):329–338. doi: 10.1002/ijc.2910420305. [DOI] [PubMed] [Google Scholar]
  54. Fåhraeus R., Jansson A., Ricksten A., Sjöblom A., Rymo L. Epstein-Barr virus-encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element. Proc Natl Acad Sci U S A. 1990 Oct;87(19):7390–7394. doi: 10.1073/pnas.87.19.7390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Gaston J. S., Rickinson A. B., Epstein M. A. Cross-reactivity of self-HLA-restricted Epstein-Barr virus-specific cytotoxic T lymphocytes for allo-HLA determinants. J Exp Med. 1983 Dec 1;158(6):1804–1821. doi: 10.1084/jem.158.6.1804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Gavioli R., Kurilla M. G., de Campos-Lima P. O., Wallace L. E., Dolcetti R., Murray R. J., Rickinson A. B., Masucci M. G. Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. J Virol. 1993 Mar;67(3):1572–1578. doi: 10.1128/jvi.67.3.1572-1578.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Geddes J. F., Bhattacharjee M. B., Savage K., Scaravilli F., McLaughlin J. E. Primary cerebral lymphoma: a study of 47 cases probed for Epstein-Barr virus genome. J Clin Pathol. 1992 Jul;45(7):587–590. doi: 10.1136/jcp.45.7.587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Gerber P., Lucas S., Nonoyama M., Perlin E., Goldstein L. I. Oral excretion of Epstein-Barr virus by healthy subjects and patients with infectious mononucleosis. Lancet. 1972 Nov 11;2(7785):988–989. doi: 10.1016/s0140-6736(72)92402-6. [DOI] [PubMed] [Google Scholar]
  59. Gergely L., Klein G., Ernberg I. Host cell macromolecular synthesis in cells containing EBV-induced early antigens, studied by combined immunofluorescence and radioautography. Virology. 1971 Jul;45(1):22–29. doi: 10.1016/0042-6822(71)90108-5. [DOI] [PubMed] [Google Scholar]
  60. Geser A., Lenoir G. M., Anvret M., Bornkamm G., Klein G., Williams E. H., Wright D. H., De-The G. Epstein-Barr virus markers in a series of Burkitt's lymphomas from the West Nile District, Uganda. Eur J Cancer Clin Oncol. 1983 Oct;19(10):1393–1404. doi: 10.1016/0277-5379(93)90009-t. [DOI] [PubMed] [Google Scholar]
  61. Geser A., de Thé G., Lenoir G., Day N. E., Williams E. H. Final case reporting from the Ugandan prospective study of the relationship between EBV and Burkitt's lymphoma. Int J Cancer. 1982 Apr 15;29(4):397–400. doi: 10.1002/ijc.2910290406. [DOI] [PubMed] [Google Scholar]
  62. Given D., Kieff E. DNA of Epstein-Barr virus. IV. Linkage map of restriction enzyme fragments of the B95-8 and W91 strains of Epstein-Barr Virus. J Virol. 1978 Nov;28(2):524–542. doi: 10.1128/jvi.28.2.524-542.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Given D., Kieff E. DNA of Epstein-Barr virus. VI. Mapping of the internal tandem reiteration. J Virol. 1979 Aug;31(2):315–324. doi: 10.1128/jvi.31.2.315-324.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Glickman J. N., Howe J. G., Steitz J. A. Structural analyses of EBER1 and EBER2 ribonucleoprotein particles present in Epstein-Barr virus-infected cells. J Virol. 1988 Mar;62(3):902–911. doi: 10.1128/jvi.62.3.902-911.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Gordon J., Ley S. C., Melamed M. D., Aman P., Hughes-Jones N. C. Soluble factor requirements for the autostimulatory growth of B lymphoblasts immortalized by Epstein-Barr virus. J Exp Med. 1984 May 1;159(5):1554–1559. doi: 10.1084/jem.159.5.1554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Greenspan J. S., Greenspan D., Lennette E. T., Abrams D. I., Conant M. A., Petersen V., Freese U. K. Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. N Engl J Med. 1985 Dec 19;313(25):1564–1571. doi: 10.1056/NEJM198512193132502. [DOI] [PubMed] [Google Scholar]
  67. Gregory C. D., Murray R. J., Edwards C. F., Rickinson A. B. Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J Exp Med. 1988 Jun 1;167(6):1811–1824. doi: 10.1084/jem.167.6.1811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Grierson H. L., Skare J., Hawk J., Pauza M., Purtilo D. T. Immunoglobulin class and subclass deficiencies prior to Epstein-Barr virus infection in males with X-linked lymphoproliferative disease. Am J Med Genet. 1991 Sep 1;40(3):294–297. doi: 10.1002/ajmg.1320400309. [DOI] [PubMed] [Google Scholar]
  69. Gutensohn N., Cole P. Epidemiology of Hodgkin's disease. Semin Oncol. 1980 Jun;7(2):92–102. [PubMed] [Google Scholar]
  70. Hamilton-Dutoit S. J., Pallesen G. A survey of Epstein-Barr virus gene expression in sporadic non-Hodgkin's lymphomas. Detection of Epstein-Barr virus in a subset of peripheral T-cell lymphomas. Am J Pathol. 1992 Jun;140(6):1315–1325. [PMC free article] [PubMed] [Google Scholar]
  71. Hammerschmidt W., Sugden B., Baichwal V. R. The transforming domain alone of the latent membrane protein of Epstein-Barr virus is toxic to cells when expressed at high levels. J Virol. 1989 Jun;63(6):2469–2475. doi: 10.1128/jvi.63.6.2469-2475.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Harabuchi Y., Yamanaka N., Kataura A., Imai S., Kinoshita T., Mizuno F., Osato T. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet. 1990 Jan 20;335(8682):128–130. doi: 10.1016/0140-6736(90)90002-m. [DOI] [PubMed] [Google Scholar]
  73. Hasler F., Bluestein H. G., Zvaifler N. J., Epstein L. B. Analysis of the defects responsible for the impaired regulation of Epstein-Barr virus-induced B cell proliferation by rheumatoid arthritis lymphocytes. I. Diminished gamma interferon production in response to autologous stimulation. J Exp Med. 1983 Jan 1;157(1):173–188. doi: 10.1084/jem.157.1.173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Hatfull G., Bankier A. T., Barrell B. G., Farrell P. J. Sequence analysis of Raji Epstein-Barr virus DNA. Virology. 1988 Jun;164(2):334–340. doi: 10.1016/0042-6822(88)90546-6. [DOI] [PubMed] [Google Scholar]
  75. Heller M., Dambaugh T., Kieff E. Epstein-Barr virus DNA. IX. Variation among viral DNAs from producer and nonproducer infected cells. J Virol. 1981 May;38(2):632–648. doi: 10.1128/jvi.38.2.632-648.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Heller M., Flemington E., Kieff E., Deininger P. Repeat arrays in cellular DNA related to the Epstein-Barr virus IR3 repeat. Mol Cell Biol. 1985 Mar;5(3):457–465. doi: 10.1128/mcb.5.3.457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Heller M., Gerber P., Kieff E. DNA of herpesvirus pan, a third member of the Epstein-Barr virus-Herpesvirus papio group. J Virol. 1982 Mar;41(3):931–939. doi: 10.1128/jvi.41.3.931-939.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Henderson S., Rowe M., Gregory C., Croom-Carter D., Wang F., Longnecker R., Kieff E., Rickinson A. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell. 1991 Jun 28;65(7):1107–1115. doi: 10.1016/0092-8674(91)90007-l. [DOI] [PubMed] [Google Scholar]
  79. Henie G., Henle W., Horwitz C. A. Antibodies to Epstein-Barr virus-associated nuclear antigen in infectious mononucleosis. J Infect Dis. 1974 Sep;130(3):231–239. doi: 10.1093/infdis/130.3.231. [DOI] [PubMed] [Google Scholar]
  80. Henle G., Henle W., Clifford P., Diehl V., Kafuko G. W., Kirya B. G., Klein G., Morrow R. H., Munube G. M., Pike P. Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. J Natl Cancer Inst. 1969 Nov;43(5):1147–1157. [PubMed] [Google Scholar]
  81. Henle G., Henle W. Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol. 1966 Mar;91(3):1248–1256. doi: 10.1128/jb.91.3.1248-1256.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Henle G., Henle W. Studies on cell lines derived from Burkitt's lymphoma. Trans N Y Acad Sci. 1966 Nov;29(1):71–79. doi: 10.1111/j.2164-0947.1966.tb02253.x. [DOI] [PubMed] [Google Scholar]
  83. Henle W., Diehl V., Kohn G., Zur Hausen H., Henle G. Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science. 1967 Sep 1;157(3792):1064–1065. doi: 10.1126/science.157.3792.1064. [DOI] [PubMed] [Google Scholar]
  84. Henle W., Henle G., Zajac B. A., Pearson G., Waubke R., Scriba M. Differential reactivity of human serums with early antigens induced by Epstein-Barr virus. Science. 1970 Jul 10;169(3941):188–190. doi: 10.1126/science.169.3941.188. [DOI] [PubMed] [Google Scholar]
  85. Hennessy K., Heller M., van Santen V., Kieff E. Simple repeat array in Epstein-Barr virus DNA encodes part of the Epstein-Barr nuclear antigen. Science. 1983 Jun 24;220(4604):1396–1398. doi: 10.1126/science.6304878. [DOI] [PubMed] [Google Scholar]
  86. Hennessy K., Kieff E. One of two Epstein-Barr virus nuclear antigens contains a glycine-alanine copolymer domain. Proc Natl Acad Sci U S A. 1983 Sep;80(18):5665–5669. doi: 10.1073/pnas.80.18.5665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Herbst H., Dallenbach F., Hummel M., Niedobitek G., Pileri S., Müller-Lantzsch N., Stein H. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4766–4770. doi: 10.1073/pnas.88.11.4766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Herbst H., Stein H., Niedobitek G. Epstein-Barr virus and CD30+ malignant lymphomas. Crit Rev Oncog. 1993;4(2):191–239. [PubMed] [Google Scholar]
  89. Heslop H. E., Brenner M. K., Rooney C. M. Donor T cells to treat EBV-associated lymphoma. N Engl J Med. 1994 Sep 8;331(10):679–680. doi: 10.1056/NEJM199409083311017. [DOI] [PubMed] [Google Scholar]
  90. Hill A., Worth A., Elliott T., Rowland-Jones S., Brooks J., Rickinson A., McMichael A. Characterization of two Epstein-Barr virus epitopes restricted by HLA-B7. Eur J Immunol. 1995 Jan;25(1):18–24. doi: 10.1002/eji.1830250105. [DOI] [PubMed] [Google Scholar]
  91. Hu L. F., Zabarovsky E. R., Chen F., Cao S. L., Ernberg I., Klein G., Winberg G. Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J Gen Virol. 1991 Oct;72(Pt 10):2399–2409. doi: 10.1099/0022-1317-72-10-2399. [DOI] [PubMed] [Google Scholar]
  92. Huang D. P., Lo K. W., Choi P. H., Ng A. Y., Tsao S. Y., Yiu G. K., Lee J. C. Loss of heterozygosity on the short arm of chromosome 3 in nasopharyngeal carcinoma. Cancer Genet Cytogenet. 1991 Jul 1;54(1):91–99. doi: 10.1016/0165-4608(91)90035-s. [DOI] [PubMed] [Google Scholar]
  93. Inoue N., Harada S., Miyasaka N., Oya A., Yanagi K. Analysis of antibody titers to Epstein-Barr virus nuclear antigens in sera of patients with Sjögren's syndrome and with rheumatoid arthritis. J Infect Dis. 1991 Jul;164(1):22–28. doi: 10.1093/infdis/164.1.22. [DOI] [PubMed] [Google Scholar]
  94. Jondal M., Klein G., Oldstone M. B., Bokish V., Yefenof E. Surface markers on human B and T lymphocytes. VIII. Association between complement and Epstein-Barr virus receptors on human lymphoid cells. Scand J Immunol. 1976;5(4):401–410. doi: 10.1111/j.1365-3083.1976.tb00294.x. [DOI] [PubMed] [Google Scholar]
  95. Jones J. F., Shurin S., Abramowsky C., Tubbs R. R., Sciotto C. G., Wahl R., Sands J., Gottman D., Katz B. Z., Sklar J. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. N Engl J Med. 1988 Mar 24;318(12):733–741. doi: 10.1056/NEJM198803243181203. [DOI] [PubMed] [Google Scholar]
  96. Katz B. Z., Raab-Traub N., Miller G. Latent and replicating forms of Epstein-Barr virus DNA in lymphomas and lymphoproliferative diseases. J Infect Dis. 1989 Oct;160(4):589–598. doi: 10.1093/infdis/160.4.589. [DOI] [PubMed] [Google Scholar]
  97. Khanna R., Burrows S. R., Argaet V., Moss D. J. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. Int Immunol. 1994 Apr;6(4):639–645. doi: 10.1093/intimm/6.4.639. [DOI] [PubMed] [Google Scholar]
  98. Khanna R., Burrows S. R., Kurilla M. G., Jacob C. A., Misko I. S., Sculley T. B., Kieff E., Moss D. J. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med. 1992 Jul 1;176(1):169–176. doi: 10.1084/jem.176.1.169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Khanna R., Burrows S. R., Suhrbier A., Jacob C. A., Griffin H., Misko I. S., Sculley T. B., Rowe M., Rickinson A. B., Moss D. J. EBV peptide epitope sensitization restores human cytotoxic T cell recognition of Burkitt's lymphoma cells. Evidence for a critical role for ICAM-2. J Immunol. 1993 Jun 1;150(11):5154–5162. [PubMed] [Google Scholar]
  100. Khanna R., Jacob C. A., Burrows S. R., Kurilla M. G., Kieff E., Misko I. S., Sculley T. B., Moss D. J. Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T cells. Immunology. 1991 Nov;74(3):504–510. [PMC free article] [PubMed] [Google Scholar]
  101. Khanna R., Jacob C. A., Burrows S. R., Moss D. J. Presentation of endogenous viral peptide epitopes by anti-CD40 stimulated human B cells following recombinant vaccinia infection. J Immunol Methods. 1993 Aug 26;164(1):41–49. doi: 10.1016/0022-1759(93)90274-b. [DOI] [PubMed] [Google Scholar]
  102. Kintner C., Sugden B. Conservation and progressive methylation of Epstein-Barr viral DNA sequences in transformed cells. J Virol. 1981 Apr;38(1):305–316. doi: 10.1128/jvi.38.1.305-316.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  103. Klein G. Immunological surveillance against neoplasia. Harvey Lect. 1973;(69):71–102. [PubMed] [Google Scholar]
  104. Klein G. Lymphoma development in mice and humans: diversity of initiation is followed by convergent cytogenetic evolution. Proc Natl Acad Sci U S A. 1979 May;76(5):2442–2446. doi: 10.1073/pnas.76.5.2442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Klein G., Svedmyr E., Jondal M., Persson P. O. EBV-determined nuclear antigen (EBNA)-positive cells in the peripheral blood of infectious mononucleosis patients. Int J Cancer. 1976 Jan 15;17(1):21–26. doi: 10.1002/ijc.2910170105. [DOI] [PubMed] [Google Scholar]
  106. Klein G. Viral latency and transformation: the strategy of Epstein-Barr virus. Cell. 1989 Jul 14;58(1):5–8. doi: 10.1016/0092-8674(89)90394-2. [DOI] [PubMed] [Google Scholar]
  107. Knecht H., Bachmann E., Joske D. J., Sahli R., Eméry-Goodman A., Casanova J. L., Zilić M., Bachmann F., Odermatt B. F. Molecular analysis of the LMP (latent membrane protein) oncogene in Hodgkin's disease. Leukemia. 1993 Apr;7(4):580–585. [PubMed] [Google Scholar]
  108. Lam K. M., Syed N., Whittle H., Crawford D. H. Circulating Epstein-Barr virus-carrying B cells in acute malaria. Lancet. 1991 Apr 13;337(8746):876–878. doi: 10.1016/0140-6736(91)90203-2. [DOI] [PubMed] [Google Scholar]
  109. Lear A. L., Rowe M., Kurilla M. G., Lee S., Henderson S., Kieff E., Rickinson A. B. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle. J Virol. 1992 Dec;66(12):7461–7468. doi: 10.1128/jvi.66.12.7461-7468.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  110. Lee S. P., Morgan S., Skinner J., Thomas W. A., Jones S. R., Sutton J., Khanna R., Whittle H. C., Rickinson A. B. Epstein-Barr virus isolates with the major HLA B35.01-restricted cytotoxic T lymphocyte epitope are prevalent in a highly B35.01-positive African population. Eur J Immunol. 1995 Jan;25(1):102–110. doi: 10.1002/eji.1830250119. [DOI] [PubMed] [Google Scholar]
  111. Lee S. P., Thomas W. A., Murray R. J., Khanim F., Kaur S., Young L. S., Rowe M., Kurilla M., Rickinson A. B. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol. 1993 Dec;67(12):7428–7435. doi: 10.1128/jvi.67.12.7428-7435.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Lenoir G. M., Preud'homme J. L., Bernheim A., Berger R. Correlation between immunoglobulin light chain expression and variant translocation in Burkitt's lymphoma. Nature. 1982 Jul 29;298(5873):474–476. doi: 10.1038/298474a0. [DOI] [PubMed] [Google Scholar]
  113. Lin J. C., Shaw J. E., Smith M. C., Pagano J. S. Effect of 12-O-tetradecanoyl-phorbol-13-acetate on the replication of Epstein-Barr virus. I. Characterization of viral DNA. Virology. 1979 Nov;99(1):183–187. doi: 10.1016/0042-6822(79)90052-7. [DOI] [PubMed] [Google Scholar]
  114. Ljunggren H. G., Stam N. J., Ohlén C., Neefjes J. J., Höglund P., Heemels M. T., Bastin J., Schumacher T. N., Townsend A., Kärre K. Empty MHC class I molecules come out in the cold. Nature. 1990 Aug 2;346(6283):476–480. doi: 10.1038/346476a0. [DOI] [PubMed] [Google Scholar]
  115. Locker J., Nalesnik M. Molecular genetic analysis of lymphoid tumors arising after organ transplantation. Am J Pathol. 1989 Dec;135(6):977–987. [PMC free article] [PubMed] [Google Scholar]
  116. Lu S. J., Day N. E., Degos L., Lepage V., Wang P. C., Chan S. H., Simons M., McKnight B., Easton D., Zeng Y. Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region. Nature. 1990 Aug 2;346(6283):470–471. doi: 10.1038/346470a0. [DOI] [PubMed] [Google Scholar]
  117. Luka J., Kallin B., Klein G. Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology. 1979 Apr 15;94(1):228–231. doi: 10.1016/0042-6822(79)90455-0. [DOI] [PubMed] [Google Scholar]
  118. Magrath I. The pathogenesis of Burkitt's lymphoma. Adv Cancer Res. 1990;55:133–270. doi: 10.1016/s0065-230x(08)60470-4. [DOI] [PubMed] [Google Scholar]
  119. Manolov G., Manolova Y., Klein G., Lenoir G., Levan A. Alternative involvement of two cytogenetically distinguishable breakpoints on chromosome 8 in Burkitt's lymphoma associated translocations. Cancer Genet Cytogenet. 1986 Feb 1;20(1-2):95–99. doi: 10.1016/0165-4608(86)90111-1. [DOI] [PubMed] [Google Scholar]
  120. Manolov G., Manolova Y. Marker band in one chromosome 14 from Burkitt lymphomas. Nature. 1972 May 5;237(5349):33–34. doi: 10.1038/237033a0. [DOI] [PubMed] [Google Scholar]
  121. Masucci M. G., Torsteindottir S., Colombani J., Brautbar C., Klein E., Klein G. Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines. Proc Natl Acad Sci U S A. 1987 Jul;84(13):4567–4571. doi: 10.1073/pnas.84.13.4567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  122. Misko I. S., Moss D. J., Pope J. H. HLA antigen-related restriction of T lymphocyte cytotoxicity to Epstein-Barr virus. Proc Natl Acad Sci U S A. 1980 Jul;77(7):4247–4250. doi: 10.1073/pnas.77.7.4247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  123. Misko I. S., Pope J. H., Hütter R., Soszynski T. D., Kane R. G. HLA-DR-antigen-associated restriction of EBV-specific cytotoxic T-cell colonies. Int J Cancer. 1984 Feb 15;33(2):239–243. doi: 10.1002/ijc.2910330212. [DOI] [PubMed] [Google Scholar]
  124. Misko I. S., Pope J. H., Hütter R., Soszynski T. D., Kane R. G. HLA-DR-antigen-associated restriction of EBV-specific cytotoxic T-cell colonies. Int J Cancer. 1984 Feb 15;33(2):239–243. doi: 10.1002/ijc.2910330212. [DOI] [PubMed] [Google Scholar]
  125. Misko I. S., Sculley T. B., Schmidt C., Moss D. J., Soszynski T., Burman K. Composite response of naive T cells to stimulation with the autologous lymphoblastoid cell line is mediated by CD4 cytotoxic T cell clones and includes an Epstein-Barr virus-specific component. Cell Immunol. 1991 Feb;132(2):295–307. doi: 10.1016/0008-8749(91)90029-b. [DOI] [PubMed] [Google Scholar]
  126. Miyawaki T., Kasahara Y., Kanegane H., Ohta K., Yokoi T., Yachie A., Taniguchi N. Expression of CD45R0 (UCHL1) by CD4+ and CD8+ T cells as a sign of in vivo activation in infectious mononucleosis. Clin Exp Immunol. 1991 Mar;83(3):447–451. doi: 10.1111/j.1365-2249.1991.tb05659.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  127. Momburg F., Ortiz-Navarrete V., Neefjes J., Goulmy E., van de Wal Y., Spits H., Powis S. J., Butcher G. W., Howard J. C., Walden P. Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation. Nature. 1992 Nov 12;360(6400):174–177. doi: 10.1038/360174a0. [DOI] [PubMed] [Google Scholar]
  128. Moore K. W., Vieira P., Fiorentino D. F., Trounstine M. L., Khan T. A., Mosmann T. R. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science. 1990 Jun 8;248(4960):1230–1234. doi: 10.1126/science.2161559. [DOI] [PubMed] [Google Scholar]
  129. Morgan A. J., Finerty S., Lovgren K., Scullion F. T., Morein B. Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes. J Gen Virol. 1988 Aug;69(Pt 8):2093–2096. doi: 10.1099/0022-1317-69-8-2093. [DOI] [PubMed] [Google Scholar]
  130. Morgan A. J., Mackett M., Finerty S., Arrand J. R., Scullion F. T., Epstein M. A. Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas. J Med Virol. 1988 Jun;25(2):189–195. doi: 10.1002/jmv.1890250209. [DOI] [PubMed] [Google Scholar]
  131. Moss D. J., Burrows S. R., Baxter G. D., Lavin M. F. T cell-T cell killing is induced by specific epitopes: evidence for an apoptotic mechanism. J Exp Med. 1991 Mar 1;173(3):681–686. doi: 10.1084/jem.173.3.681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  132. Moss D. J., Burrows S. R., Castelino D. J., Kane R. G., Pope J. H., Rickinson A. B., Alpers M. P., Heywood P. F. A comparison of Epstein-Barr virus-specific T-cell immunity in malaria-endemic and -nonendemic regions of Papua New Guinea. Int J Cancer. 1983 Jun 15;31(6):727–732. doi: 10.1002/ijc.2910310609. [DOI] [PubMed] [Google Scholar]
  133. Moss D. J., Burrows S. R., Khanna R., Misko I. S., Sculley T. B. Immune surveillance against Epstein-Barr virus. Semin Immunol. 1992 Apr;4(2):97–104. [PubMed] [Google Scholar]
  134. Moss D. J., Burrows S. R., Suhrbier A., Khanna R. Potential antigenic targets on Epstein-Barr virus-associated tumours and the host response. Ciba Found Symp. 1994;187:4–20. doi: 10.1002/9780470514672.ch2. [DOI] [PubMed] [Google Scholar]
  135. Moss D. J., Chan S. H., Burrows S. R., Chew T. S., Kane R. G., Staples J. A., Kunaratnam N. Epstein-Barr virus specific T-cell response in nasopharyngeal carcinoma patients. Int J Cancer. 1983 Sep 15;32(3):301–305. doi: 10.1002/ijc.2910320307. [DOI] [PubMed] [Google Scholar]
  136. Moss D. J., Klestov A., Burrows S., Kane R. G. A comparison of Epstein-Barr virus-specific T-cell immunity in rheumatoid arthritis and osteoarthritis patients. Aust J Exp Biol Med Sci. 1983 Oct;61(Pt 5):509–516. doi: 10.1038/icb.1983.48. [DOI] [PubMed] [Google Scholar]
  137. Moss D. J., Misko I. S., Burrows S. R., Burman K., McCarthy R., Sculley T. B. Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants. Nature. 1988 Feb 25;331(6158):719–721. doi: 10.1038/331719a0. [DOI] [PubMed] [Google Scholar]
  138. Moss D. J., Rickinson A. B., Pope J. H. Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes. Int J Cancer. 1978 Dec;22(6):662–668. doi: 10.1002/ijc.2910220604. [DOI] [PubMed] [Google Scholar]
  139. Moss D. J., Rickinson A. B., Pope J. H. Long-term T-cell-mediated immunity to Epstein-Barr virus in man. III. Activation of cytotoxic T cells in virus-infected leukocyte cultures. Int J Cancer. 1979 May 15;23(5):618–625. doi: 10.1002/ijc.2910230506. [DOI] [PubMed] [Google Scholar]
  140. Moss D. J., Rickinson A. B., Wallace L. E., Epstein M. A. Sequential appearance of Epstein-Barr virus nuclear and lymphocyte-detected membrane antigens in B cell transformation. Nature. 1981 Jun 25;291(5817):664–666. doi: 10.1038/291664a0. [DOI] [PubMed] [Google Scholar]
  141. Moss D. J., Wallace L. E., Rickinson A. B., Epstein M. A. Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. I. Specificity and HLA restriction of effector cells reactivated in vitro. Eur J Immunol. 1981 Sep;11(9):686–693. doi: 10.1002/eji.1830110904. [DOI] [PubMed] [Google Scholar]
  142. Mueller-Lantzsch N., Georg B., Yamamoto N., zur Hausen H. Epstein-Barr virus-induced proteins. III. Analysis of polypeptides from P3HR-1-EBV-superinfected NC37 cells by immunoprecipitation. Virology. 1980 Apr 15;102(1):231–233. doi: 10.1016/0042-6822(80)90087-2. [DOI] [PubMed] [Google Scholar]
  143. Murphy J. K., Young L. S., Bevan I. S., Lewis F. A., Dockey D., Ironside J. W., O'Brien C. J., Wells M. Demonstration of Epstein-Barr virus in primary brain lymphoma by in situ DNA hybridisation in paraffin wax embedded tissue. J Clin Pathol. 1990 Mar;43(3):220–223. doi: 10.1136/jcp.43.3.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  144. Murray R. J., Kurilla M. G., Brooks J. M., Thomas W. A., Rowe M., Kieff E., Rickinson A. B. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med. 1992 Jul 1;176(1):157–168. doi: 10.1084/jem.176.1.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  145. Murray R. J., Kurilla M. G., Griffin H. M., Brooks J. M., Mackett M., Arrand J. R., Rowe M., Burrows S. R., Moss D. J., Kieff E. Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses. Proc Natl Acad Sci U S A. 1990 Apr;87(8):2906–2910. doi: 10.1073/pnas.87.8.2906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  146. Muñoz N., Davidson R. J., Witthoff B., Ericsson J. E., De-Thé G. Infectious mononucleosis and Hodgkin's disease. Int J Cancer. 1978 Jul 15;22(1):10–13. doi: 10.1002/ijc.2910220104. [DOI] [PubMed] [Google Scholar]
  147. Nahill S. R., Welsh R. M. High frequency of cross-reactive cytotoxic T lymphocytes elicited during the virus-induced polyclonal cytotoxic T lymphocyte response. J Exp Med. 1993 Feb 1;177(2):317–327. doi: 10.1084/jem.177.2.317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  148. Neri A., Barriga F., Inghirami G., Knowles D. M., Neequaye J., Magrath I. T., Dalla-Favera R. Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma. Blood. 1991 Mar 1;77(5):1092–1095. [PubMed] [Google Scholar]
  149. Nilsson K., Klein G., Henle W., Henle G. The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV. Int J Cancer. 1971 Nov 15;8(3):443–450. doi: 10.1002/ijc.2910080312. [DOI] [PubMed] [Google Scholar]
  150. Nonoyama M., Pagano J. S. Homology between Epstein-Barr virus DNA and viral DNA from Burkitt's lymphoma and nasopharyngeal carcinoma determined by DNA-DNA reassociation kinetics. Nature. 1973 Mar 2;242(5392):44–47. doi: 10.1038/242044a0. [DOI] [PubMed] [Google Scholar]
  151. Okano M., Thiele G. M., Gross T. G., Davis J. R., Purtilo D. T. Differential cellular susceptibility to Epstein-Barr virus infection in a patient with X-linked lymphoproliferative disease. J Med Virol. 1990 Sep;32(1):47–52. doi: 10.1002/jmv.1890320108. [DOI] [PubMed] [Google Scholar]
  152. Okano M., Thiele G. M., Kobayashi R. H., Davis J. R., Synovec M. S., Grierson H. L., Jaffe H. S., Purtilo D. T. Interferon-gamma in a family with X-linked lymphoproliferative syndrome with acute Epstein-Barr virus infection. J Clin Immunol. 1989 Jan;9(1):48–54. doi: 10.1007/BF00917127. [DOI] [PubMed] [Google Scholar]
  153. Old L. J., Boyse E. A., Oettgen H. F., Harven E. D., Geering G., Williamson B., Clifford P. Precipitating antibody in human serum to an antigen present in cultured burkitt's lymphoma cells. Proc Natl Acad Sci U S A. 1966 Dec;56(6):1699–1704. doi: 10.1073/pnas.56.6.1699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  154. Pallesen G., Hamilton-Dutoit S. J., Rowe M., Young L. S. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet. 1991 Feb 9;337(8737):320–322. doi: 10.1016/0140-6736(91)90943-j. [DOI] [PubMed] [Google Scholar]
  155. Pallesen G., Sandvej K., Hamilton-Dutoit S. J., Rowe M., Young L. S. Activation of Epstein-Barr virus replication in Hodgkin and Reed-Sternberg cells. Blood. 1991 Sep 1;78(5):1162–1165. [PubMed] [Google Scholar]
  156. Patarroyo M., Blazar B., Pearson G., Klein E., Klein G. Induction of the EBV cycle in B-lymphocyte-derived lines is accompanied by increased natural killer (NK) sensitivity and the expression of EBV-related antigen(s) detected by the ADCC reaction. Int J Cancer. 1980 Sep 15;26(3):365–371. doi: 10.1002/ijc.2910260317. [DOI] [PubMed] [Google Scholar]
  157. Pearson G. R., Luka J., Petti L., Sample J., Birkenbach M., Braun D., Kieff E. Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex. Virology. 1987 Sep;160(1):151–161. doi: 10.1016/0042-6822(87)90055-9. [DOI] [PubMed] [Google Scholar]
  158. Pope J. H. Establishment of cell lines from peripheral leucocytes in infectious mononucleosis. Nature. 1967 Nov 25;216(5117):810–811. doi: 10.1038/216810a0. [DOI] [PubMed] [Google Scholar]
  159. Pope J. H., Horne M. K., Scott W. Transformation of foetal human keukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int J Cancer. 1968 Nov 15;3(6):857–866. doi: 10.1002/ijc.2910030619. [DOI] [PubMed] [Google Scholar]
  160. Pothen S., Cao T., Smith R., Levine P. H., Levine A., Pearson G. R. Identification of T- and B-cell epitopes associated with a restricted component of the Epstein-Barr virus-induced early antigen complex. Int J Cancer. 1993 Jan 21;53(2):199–204. doi: 10.1002/ijc.2910530204. [DOI] [PubMed] [Google Scholar]
  161. Pothen S., Richert J. R., Pearson G. R. Human T-cell recognition of Epstein-Barr virus-induced replication antigen complexes. Int J Cancer. 1991 Nov 11;49(5):656–660. doi: 10.1002/ijc.2910490505. [DOI] [PubMed] [Google Scholar]
  162. Powis S. J., Townsend A. R., Deverson E. V., Bastin J., Butcher G. W., Howard J. C. Restoration of antigen presentation to the mutant cell line RMA-S by an MHC-linked transporter. Nature. 1991 Dec 19;354(6354):528–531. doi: 10.1038/354528a0. [DOI] [PubMed] [Google Scholar]
  163. Purtilo D. T., Cassel C. K., Yang J. P., Harper R. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet. 1975 Apr 26;1(7913):935–940. doi: 10.1016/s0140-6736(75)92004-8. [DOI] [PubMed] [Google Scholar]
  164. Purtilo D. T. Defective immune surveillance in viral carcinogenesis. Lab Invest. 1984 Oct;51(4):373–385. [PubMed] [Google Scholar]
  165. Purtilo D. T., Grierson H. L., Ochs H., Skare J. Detection of X-linked lymphoproliferative disease using molecular and immunovirologic markers. Am J Med. 1989 Oct;87(4):421–424. doi: 10.1016/s0002-9343(89)80825-3. [DOI] [PubMed] [Google Scholar]
  166. Purtilo D. T., Strobach R. S., Okano M., Davis J. R. Epstein-Barr virus-associated lymphoproliferative disorders. Lab Invest. 1992 Jul;67(1):5–23. [PubMed] [Google Scholar]
  167. Raab-Traub N., Rajadurai P., Flynn K., Lanier A. P. Epstein-Barr virus infection in carcinoma of the salivary gland. J Virol. 1991 Dec;65(12):7032–7036. doi: 10.1128/jvi.65.12.7032-7036.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  168. Rickinson A. B., Epstein M. A., Crawford D. H. Absence of infectious Epstein-Barr virus in blood in acute infectious mononucleosis. Nature. 1975 Nov 20;258(5532):236–236. doi: 10.1038/258236a0. [DOI] [PubMed] [Google Scholar]
  169. Rickinson A. B., Moss D. J., Pope J. H., Ahlberg N. Long-term T-cell-mediated immunity to Epstein-Barr virus in man. IV. Development of T-cell memory in convalescent infectious mononucleosis patients. Int J Cancer. 1980 Jan 15;25(1):59–65. doi: 10.1002/ijc.2910250108. [DOI] [PubMed] [Google Scholar]
  170. Rickinson A. B., Moss D. J., Pope J. H. Long-term C-cell-mediated immunity to Epstein-Barr virus in man. II. Components necessary for regression in virus-infected leukocyte cultures. Int J Cancer. 1979 May 15;23(5):610–617. doi: 10.1002/ijc.2910230505. [DOI] [PubMed] [Google Scholar]
  171. Rickinson A. B., Moss D. J., Wallace L. E., Rowe M., Misko I. S., Epstein M. A., Pope J. H. Long-term T-cell-mediated immunity to Epstein-Barr virus. Cancer Res. 1981 Nov;41(11 Pt 1):4216–4221. [PubMed] [Google Scholar]
  172. Rickinson A. B., Murray R. J., Brooks J., Griffin H., Moss D. J., Masucci M. G. T cell recognition of Epstein-Barr virus associated lymphomas. Cancer Surv. 1992;13:53–80. [PubMed] [Google Scholar]
  173. Rickinson A. B., Young L. S., Rowe M. Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J Virol. 1987 May;61(5):1310–1317. doi: 10.1128/jvi.61.5.1310-1317.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  174. Rooney C. M., Edwards C. F., Lenoir G. M., Rupani H., Rickinson A. B. Differential activation of cytotoxic responses by Burkitt's lymphoma (BL)-cell lines: relationship to the BL-cell surface phenotype. Cell Immunol. 1986 Oct 1;102(1):99–112. doi: 10.1016/0008-8749(86)90329-1. [DOI] [PubMed] [Google Scholar]
  175. Rooney C. M., Gregory C. D., Rowe M., Finerty S., Edwards C., Rupani H., Rickinson A. B. Endemic Burkitt's lymphoma: phenotypic analysis of tumor biopsy cells and of derived tumor cell lines. J Natl Cancer Inst. 1986 Sep;77(3):681–687. doi: 10.1093/jnci/77.3.681. [DOI] [PubMed] [Google Scholar]
  176. Rooney C. M., Rickinson A. B., Moss D. J., Lenoir G. M., Epstein M. A. Cell-mediated immunosurveillance mechanisms and the pathogenesis of Burkitt's lymphoma. IARC Sci Publ. 1985;(60):249–264. [PubMed] [Google Scholar]
  177. Rooney C. M., Rickinson A. B., Moss D. J., Lenoir G. M., Epstein M. A. Paired Epstein-Barr virus-carrying lymphoma and lymphoblastoid cell lines from Burkitt's lymphoma patients: comparative sensitivity to non-specific and to allo-specific cytotoxic responses in vitro. Int J Cancer. 1984 Sep 15;34(3):339–348. doi: 10.1002/ijc.2910340310. [DOI] [PubMed] [Google Scholar]
  178. Rooney C. M., Rowe M., Wallace L. E., Rickinson A. B. Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance. Nature. 1985 Oct 17;317(6038):629–631. doi: 10.1038/317629a0. [DOI] [PubMed] [Google Scholar]
  179. Rooney C. M., Smith C. A., Ng C. Y., Loftin S., Li C., Krance R. A., Brenner M. K., Heslop H. E. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995 Jan 7;345(8941):9–13. doi: 10.1016/s0140-6736(95)91150-2. [DOI] [PubMed] [Google Scholar]
  180. Rosdahl N., Larsen S. O., Clemmesen J. Hodgkin's disease in patients with previous infectious mononucleosis: 30 years' experience. Br Med J. 1974 May 4;2(5913):253–256. doi: 10.1136/bmj.2.5913.253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  181. Rousset F., Souillet G., Roncarolo M. G., Lamelin J. P. Studies of EBV-lymphoid cell interactions in two patients with the X-linked lymphoproliferative syndrome: normal EBV-specific HLA-restricted cytotoxicity. Clin Exp Immunol. 1986 Feb;63(2):280–289. [PMC free article] [PubMed] [Google Scholar]
  182. Rowe D. T., Rowe M., Evan G. I., Wallace L. E., Farrell P. J., Rickinson A. B. Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J. 1986 Oct;5(10):2599–2607. doi: 10.1002/j.1460-2075.1986.tb04540.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  183. Rowe M., Finke J., Szigeti R., Klein G. Characterization of the serological response in man to the latent membrane protein and the six nuclear antigens encoded by Epstein-Barr virus. J Gen Virol. 1988 Jun;69(Pt 6):1217–1228. doi: 10.1099/0022-1317-69-6-1217. [DOI] [PubMed] [Google Scholar]
  184. Rowe M., Lear A. L., Croom-Carter D., Davies A. H., Rickinson A. B. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol. 1992 Jan;66(1):122–131. doi: 10.1128/jvi.66.1.122-131.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  185. Rowe M., Rowe D. T., Gregory C. D., Young L. S., Farrell P. J., Rupani H., Rickinson A. B. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 1987 Sep;6(9):2743–2751. doi: 10.1002/j.1460-2075.1987.tb02568.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  186. Royston I., Sullivan J. L., Periman P. O., Perlin E. Cell-mediated immunity to Epstein-Barr-virus-transformed lymphoblastoid cells in acute infectious mononucleosis. N Engl J Med. 1975 Dec 4;293(23):1159–1163. doi: 10.1056/NEJM197512042932301. [DOI] [PubMed] [Google Scholar]
  187. Saemundsen A. K., Kallin B., Klein G. Effect of n-butyrate on cellular and viral DNA synthesis in cells latently infected with Epstein-Barr virus. Virology. 1980 Dec;107(2):557–561. doi: 10.1016/0042-6822(80)90326-8. [DOI] [PubMed] [Google Scholar]
  188. Sample J., Young L., Martin B., Chatman T., Kieff E., Rickinson A., Kieff E. Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol. 1990 Sep;64(9):4084–4092. doi: 10.1128/jvi.64.9.4084-4092.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  189. Sanger W. G., Grierson H. L., Skare J., Wyandt H., Pirruccello S., Fordyce R., Purtilo D. T. Partial Xq25 deletion in a family with the X-linked lymphoproliferative disease (XLP) Cancer Genet Cytogenet. 1990 Jul 15;47(2):163–169. doi: 10.1016/0165-4608(90)90026-7. [DOI] [PubMed] [Google Scholar]
  190. Schendel D. J., Reinhardt C., Nelson P. J., Maget B., Pullen L., Bornkamm G. W., Steinle A. Cytotoxic T lymphocytes show HLA-C-restricted recognition of EBV-bearing cells and allorecognition of HLA class I molecules presenting self-peptides. J Immunol. 1992 Oct 1;149(7):2406–2414. [PubMed] [Google Scholar]
  191. Schmidt C., Burrows S. R., Sculley T. B., Moss D. J., Misko I. S. Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies. Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9478–9482. doi: 10.1073/pnas.88.21.9478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  192. Sculley T. B., Apolloni A., Hurren L., Moss D. J., Cooper D. A. Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects. J Infect Dis. 1990 Sep;162(3):643–648. doi: 10.1093/infdis/162.3.642. [DOI] [PubMed] [Google Scholar]
  193. Sculley T. B., Apolloni A., Stumm R., Moss D. J., Mueller-Lantczh N., Misko I. S., Cooper D. A. Expression of Epstein-Barr virus nuclear antigens 3, 4, and 6 are altered in cell lines containing B-type virus. Virology. 1989 Aug;171(2):401–408. doi: 10.1016/0042-6822(89)90608-9. [DOI] [PubMed] [Google Scholar]
  194. Seigneurin J. M., Lavoue M. F., Genoulaz O., Bornkamm G. W., Lenoir G. M. Antibody response against the Epstein-Barr virus-coded nuclear antigen2 (EBNA2) in different groups of individuals. Int J Cancer. 1987 Sep 15;40(3):349–353. doi: 10.1002/ijc.2910400311. [DOI] [PubMed] [Google Scholar]
  195. Shah W. A., Ambinder R. F., Hayward G. S., Hayward S. D. Binding of EBNA-1 to DNA creates a protease-resistant domain that encompasses the DNA recognition and dimerization functions. J Virol. 1992 Jun;66(6):3355–3362. doi: 10.1128/jvi.66.6.3355-3362.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  196. Sheldon P. J., Hemsted E. H., Papamichail M., Holborow E. J. Thymic origin of atypical lymphoid cells in infectious mononucleosis. Lancet. 1973 May 26;1(7813):1153–1155. doi: 10.1016/s0140-6736(73)91148-3. [DOI] [PubMed] [Google Scholar]
  197. Simons M. J., Wee G. B., Day N. E., Morris P. J., Shanmugaratnam K., De-Thé G. B. Immunogenetic aspects of nasopharyngeal carcinoma: I. Differences in HL-A antigen profiles between patients and control groups. Int J Cancer. 1974 Jan 15;13(1):122–134. doi: 10.1002/ijc.2910130114. [DOI] [PubMed] [Google Scholar]
  198. Simons M. J., Wee G. B., Goh E. H., Chan S. H., Shanmugaratnam K., Day N. E., de-Thé G. Immunogenetic aspects of nasopharyngeal carcinoma. IV. Increased risk in Chinese of nasopharyngeal carcinoma associated with a Chinese-related HLA profile (A2, Singapore 2). J Natl Cancer Inst. 1976 Nov;57(5):977–980. doi: 10.1093/jnci/57.5.977. [DOI] [PubMed] [Google Scholar]
  199. Sixbey J. W., Nedrud J. G., Raab-Traub N., Hanes R. A., Pagano J. S. Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med. 1984 May 10;310(19):1225–1230. doi: 10.1056/NEJM198405103101905. [DOI] [PubMed] [Google Scholar]
  200. Sixbey J. W., Shirley P., Chesney P. J., Buntin D. M., Resnick L. Detection of a second widespread strain of Epstein-Barr virus. Lancet. 1989 Sep 30;2(8666):761–765. doi: 10.1016/s0140-6736(89)90829-5. [DOI] [PubMed] [Google Scholar]
  201. Sixbey J. W., Vesterinen E. H., Nedrud J. G., Raab-Traub N., Walton L. A., Pagano J. S. Replication of Epstein-Barr virus in human epithelial cells infected in vitro. Nature. 1983 Dec 1;306(5942):480–483. doi: 10.1038/306480a0. [DOI] [PubMed] [Google Scholar]
  202. Sixbey J. W., Yao Q. Y. Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism. Science. 1992 Mar 20;255(5051):1578–1580. doi: 10.1126/science.1312750. [DOI] [PubMed] [Google Scholar]
  203. Skare J. C., Grierson H. L., Sullivan J. L., Nussbaum R. L., Purtilo D. T., Sylla B. S., Lenoir G. M., Reilly D. S., White B. N., Milunsky A. Linkage analysis of seven kindreds with the X-linked lymphoproliferative syndrome (XLP) confirms that the XLP locus is near DXS42 and DXS37. Hum Genet. 1989 Jul;82(4):354–358. doi: 10.1007/BF00273997. [DOI] [PubMed] [Google Scholar]
  204. Spies T., Bresnahan M., Bahram S., Arnold D., Blanck G., Mellins E., Pious D., DeMars R. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature. 1990 Dec 20;348(6303):744–747. doi: 10.1038/348744a0. [DOI] [PubMed] [Google Scholar]
  205. Spies T., Cerundolo V., Colonna M., Cresswell P., Townsend A., DeMars R. Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer. Nature. 1992 Feb 13;355(6361):644–646. doi: 10.1038/355644a0. [DOI] [PubMed] [Google Scholar]
  206. Spies T., DeMars R. Restored expression of major histocompatibility class I molecules by gene transfer of a putative peptide transporter. Nature. 1991 May 23;351(6324):323–324. doi: 10.1038/351323a0. [DOI] [PubMed] [Google Scholar]
  207. Strang G., Rickinson A. B. Multiple HLA class I-dependent cytotoxicities constitute the "non-HLA-restricted" response in infectious mononucleosis. Eur J Immunol. 1987 Jul;17(7):1007–1013. doi: 10.1002/eji.1830170717. [DOI] [PubMed] [Google Scholar]
  208. Su I. J., Hsieh H. C., Lin K. H., Uen W. C., Kao C. L., Chen C. J., Cheng A. L., Kadin M. E., Chen J. Y. Aggressive peripheral T-cell lymphomas containing Epstein-Barr viral DNA: a clinicopathologic and molecular analysis. Blood. 1991 Feb 15;77(4):799–808. [PubMed] [Google Scholar]
  209. Svedmyr E., Ernberg I., Seeley J., Weiland O., Masucci G., Tsukuda K., Szigeti R., Masucci M. G., Blomogren H., Berthold W. Virologic, immunologic, and clinical observations on a patient during the incubation, acute, and convalescent phases of infectious mononucleosis. Clin Immunol Immunopathol. 1984 Mar;30(3):437–450. doi: 10.1016/0090-1229(84)90029-1. [DOI] [PubMed] [Google Scholar]
  210. Svedmyr E., Jondal M. Cytotoxic effector cells specific for B Cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis. Proc Natl Acad Sci U S A. 1975 Apr;72(4):1622–1626. doi: 10.1073/pnas.72.4.1622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  211. Szigeti R., Kallin B., Dillner J., Henle G., Henle W., Lerner R. A., Rymo L., Timar L., Klein G. Epstein-Barr virus (EBV) antigen-specific leukocyte migration inhibition in infectious mononucleosis. II. Kinetics of sensitization against five EBV-encoded nuclear proteins and the latent membrane protein. Clin Immunol Immunopathol. 1989 Jun;51(3):396–405. doi: 10.1016/0090-1229(89)90037-8. [DOI] [PubMed] [Google Scholar]
  212. Takada K. Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int J Cancer. 1984 Jan 15;33(1):27–32. doi: 10.1002/ijc.2910330106. [DOI] [PubMed] [Google Scholar]
  213. Takada K., Ono Y. Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J Virol. 1989 Jan;63(1):445–449. doi: 10.1128/jvi.63.1.445-449.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  214. Takagi S., Takada K., Sairenji T. Formation of intranuclear replication compartments of Epstein-Barr virus with redistribution of BZLF1 and BMRF1 gene products. Virology. 1991 Nov;185(1):309–315. doi: 10.1016/0042-6822(91)90778-a. [DOI] [PubMed] [Google Scholar]
  215. Tatsumi E., Purtilo D. T. Epstein-Barr virus (EBV) and X-linked lymphoproliferative syndrome (XLP). AIDS Res. 1986 Dec;2 (Suppl 1):S109–S113. [PubMed] [Google Scholar]
  216. Thomas J. A., Allday M. J., Crawford D. H. Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals. Adv Cancer Res. 1991;57:329–380. doi: 10.1016/s0065-230x(08)61003-9. [DOI] [PubMed] [Google Scholar]
  217. Thomas J. A., Hotchin N. A., Allday M. J., Amlot P., Rose M., Yacoub M., Crawford D. H. Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation. 1990 May;49(5):944–953. doi: 10.1097/00007890-199005000-00022. [DOI] [PubMed] [Google Scholar]
  218. Thomson S. A., Khanna R., Gardner J., Burrows S. R., Coupar B., Moss D. J., Suhrbier A. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5845–5849. doi: 10.1073/pnas.92.13.5845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  219. Thorley-Lawson D. A., Chess L., Strominger J. L. Suppression of in vitro Epstein-Barr virus infection. A new role for adult human T lymphocytes. J Exp Med. 1977 Aug 1;146(2):495–508. doi: 10.1084/jem.146.2.495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  220. Thorley-Lawson D. A., Geilinger K. Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity. Proc Natl Acad Sci U S A. 1980 Sep;77(9):5307–5311. doi: 10.1073/pnas.77.9.5307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  221. Thorley-Lawson D. A., Poodry C. A. Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. J Virol. 1982 Aug;43(2):730–736. doi: 10.1128/jvi.43.2.730-736.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  222. Thorley-Lawson D. A., Schooley R. T., Bhan A. K., Nadler L. M. Epstein-Barr virus superinduces a new human B cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts. Cell. 1982 Sep;30(2):415–425. doi: 10.1016/0092-8674(82)90239-2. [DOI] [PubMed] [Google Scholar]
  223. Thorley-Lawson D. A. The suppression of Epstein-Barr virus infection in vitro occurs after infection but before transformation of the cell. J Immunol. 1980 Feb;124(2):745–751. [PubMed] [Google Scholar]
  224. Tomkinson B. E., Maziarz R., Sullivan J. L. Characterization of the T cell-mediated cellular cytotoxicity during acute infectious mononucleosis. J Immunol. 1989 Jul 15;143(2):660–670. [PubMed] [Google Scholar]
  225. Torsteinsdottir S., Brautbar C., Klein G., Klein E., Masucci M. G. Differential expression of HLA antigens on human B-cell lines of normal and malignant origin: a consequence of immune surveillance or a phenotypic vestige of the progenitor cells? Int J Cancer. 1988 Jun 15;41(6):913–919. doi: 10.1002/ijc.2910410625. [DOI] [PubMed] [Google Scholar]
  226. Torsteinsdottir S., Masucci M. G., Ehlin-Henriksson B., Brautbar C., Ben Bassat H., Klein G., Klein E. Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity. Proc Natl Acad Sci U S A. 1986 Aug;83(15):5620–5624. doi: 10.1073/pnas.83.15.5620. [DOI] [PMC free article] [PubMed] [Google Scholar]
  227. Tosato G., Blaese R. M. Epstein-Barr virus infection and immunoregulation in man. Adv Immunol. 1985;37:99–149. doi: 10.1016/s0065-2776(08)60339-9. [DOI] [PubMed] [Google Scholar]
  228. Trivedi P., Hu L. F., Chen F., Christensson B., Masucci M. G., Klein G., Winberg G. Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue. Eur J Cancer. 1994;30A(1):84–88. doi: 10.1016/s0959-8049(05)80024-3. [DOI] [PubMed] [Google Scholar]
  229. Tsang S. F., Wang F., Izumi K. M., Kieff E. Delineation of the cis-acting element mediating EBNA-2 transactivation of latent infection membrane protein expression. J Virol. 1991 Dec;65(12):6765–6771. doi: 10.1128/jvi.65.12.6765-6771.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  230. Tsoukas C. D., Lambris J. D. Expression of CR2/EBV receptors on human thymocytes detected by monoclonal antibodies. Eur J Immunol. 1988 Aug;18(8):1299–1302. doi: 10.1002/eji.1830180823. [DOI] [PubMed] [Google Scholar]
  231. Uehara T., Miyawaki T., Ohta K., Tamaru Y., Yokoi T., Nakamura S., Taniguchi N. Apoptotic cell death of primed CD45RO+ T lymphocytes in Epstein-Barr virus-induced infectious mononucleosis. Blood. 1992 Jul 15;80(2):452–458. [PubMed] [Google Scholar]
  232. Ulaeto D., Wallace L., Morgan A., Morein B., Rickinson A. B. In vitro T cell responses to a candidate Epstein-Barr virus vaccine: human CD4+ T cell clones specific for the major envelope glycoprotein gp340. Eur J Immunol. 1988 Nov;18(11):1689–1697. doi: 10.1002/eji.1830181106. [DOI] [PubMed] [Google Scholar]
  233. Wallace L. E., Wright J., Ulaeto D. O., Morgan A. J., Rickinson A. B. Identification of two T-cell epitopes on the candidate Epstein-Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones. J Virol. 1991 Jul;65(7):3821–3828. doi: 10.1128/jvi.65.7.3821-3828.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  234. Wang F., Gregory C., Sample C., Rowe M., Liebowitz D., Murray R., Rickinson A., Kieff E. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol. 1990 May;64(5):2309–2318. doi: 10.1128/jvi.64.5.2309-2318.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  235. Wang F., Kikutani H., Tsang S. F., Kishimoto T., Kieff E. Epstein-Barr virus nuclear protein 2 transactivates a cis-acting CD23 DNA element. J Virol. 1991 Aug;65(8):4101–4106. doi: 10.1128/jvi.65.8.4101-4106.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  236. Watry D., Hedrick J. A., Siervo S., Rhodes G., Lamberti J. J., Lambris J. D., Tsoukas C. D. Infection of human thymocytes by Epstein-Barr virus. J Exp Med. 1991 Apr 1;173(4):971–980. doi: 10.1084/jem.173.4.971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  237. Weiss L. M., Strickler J. G., Warnke R. A., Purtilo D. T., Sklar J. Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am J Pathol. 1987 Oct;129(1):86–91. [PMC free article] [PubMed] [Google Scholar]
  238. Woisetschlaeger M., Jin X. W., Yandava C. N., Furmanski L. A., Strominger J. L., Speck S. H. Role for the Epstein-Barr virus nuclear antigen 2 in viral promoter switching during initial stages of infection. Proc Natl Acad Sci U S A. 1991 May 1;88(9):3942–3946. doi: 10.1073/pnas.88.9.3942. [DOI] [PMC free article] [PubMed] [Google Scholar]
  239. Yamaoka K., Miyasaka N., Yamamoto K. Possible involvement of Epstein-Barr virus in polyclonal B cell activation in Sjögren's syndrome. Arthritis Rheum. 1988 Aug;31(8):1014–1021. doi: 10.1002/art.1780310812. [DOI] [PubMed] [Google Scholar]
  240. Yao Q. Y., Ogan P., Rowe M., Wood M., Rickinson A. B. Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers. Int J Cancer. 1989 Jan 15;43(1):67–71. doi: 10.1002/ijc.2910430115. [DOI] [PubMed] [Google Scholar]
  241. Yao Q. Y., Rickinson A. B., Epstein M. A. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer. 1985 Jan 15;35(1):35–42. doi: 10.1002/ijc.2910350107. [DOI] [PubMed] [Google Scholar]
  242. Yao Q. Y., Rowe M., Morgan A. J., Sam C. K., Prasad U., Dang H., Zeng Y., Rickinson A. B. Salivary and serum IgA antibodies to the Epstein-Barr virus glycoprotein gp340: incidence and potential for virus neutralization. Int J Cancer. 1991 Apr 22;48(1):45–50. doi: 10.1002/ijc.2910480109. [DOI] [PubMed] [Google Scholar]
  243. Young L. S., Dawson C. W., Clark D., Rupani H., Busson P., Tursz T., Johnson A., Rickinson A. B. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol. 1988 May;69(Pt 5):1051–1065. doi: 10.1099/0022-1317-69-5-1051. [DOI] [PubMed] [Google Scholar]
  244. Young L. S., Yao Q. Y., Rooney C. M., Sculley T. B., Moss D. J., Rupani H., Laux G., Bornkamm G. W., Rickinson A. B. New type B isolates of Epstein-Barr virus from Burkitt's lymphoma and from normal individuals in endemic areas. J Gen Virol. 1987 Nov;68(Pt 11):2853–2862. doi: 10.1099/0022-1317-68-11-2853. [DOI] [PubMed] [Google Scholar]
  245. Yu M. C., Ho J. H., Lai S. H., Henderson B. E. Cantonese-style salted fish as a cause of nasopharyngeal carcinoma: report of a case-control study in Hong Kong. Cancer Res. 1986 Feb;46(2):956–961. [PubMed] [Google Scholar]
  246. Zhu X. X., Zeng Y., Wolf H. Detection of IgG and IgA antibodies to Epstein-Barr virus membrane antigen in sera from patients with nasopharyngeal carcinoma and from normal individuals. Int J Cancer. 1986 May 15;37(5):689–691. doi: 10.1002/ijc.2910370508. [DOI] [PubMed] [Google Scholar]
  247. Zimber U., Adldinger H. K., Lenoir G. M., Vuillaume M., Knebel-Doeberitz M. V., Laux G., Desgranges C., Wittmann P., Freese U. K., Schneider U. Geographical prevalence of two types of Epstein-Barr virus. Virology. 1986 Oct 15;154(1):56–66. doi: 10.1016/0042-6822(86)90429-0. [DOI] [PubMed] [Google Scholar]
  248. de Campos-Lima P. O., Gavioli R., Zhang Q. J., Wallace L. E., Dolcetti R., Rowe M., Rickinson A. B., Masucci M. G. HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. Science. 1993 Apr 2;260(5104):98–100. doi: 10.1126/science.7682013. [DOI] [PubMed] [Google Scholar]
  249. de Campos-Lima P. O., Levitsky V., Brooks J., Lee S. P., Hu L. F., Rickinson A. B., Masucci M. G. T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues. J Exp Med. 1994 Apr 1;179(4):1297–1305. doi: 10.1084/jem.179.4.1297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  250. zur Hausen H., O'Neill F. J., Freese U. K., Hecker E. Persisting oncogenic herpesvirus induced by the tumour promotor TPA. Nature. 1978 Mar 23;272(5651):373–375. doi: 10.1038/272373a0. [DOI] [PubMed] [Google Scholar]

Articles from Microbiological Reviews are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES